Hematology and Bone Marrow Transplant Pharmacist Oregon Health and Sciences University Portland, Oregon, United States
Disclosure(s):
Shannon E. Palmer, PharmD, BCOP: No financial relationships to disclose
Session Description: The purpose of this session is to review therapy options for chronic graft versus host disease (cGVHD) with a focus on steroid refractory cGVHD. This presentation will focus on reviewing the pivotal REACH 3 (ruxolitinib) and ROCKstar (belumosudil) trials, as well as, the new negative front-line study INTEGRATE (ibrutinib). After reviewing the clinical data, the session will compare the agents routinely used in cGVHD and discuss sequencing, utilization for specific organ systems, and supportive care considerations. Additionally, a brief review of novel agents and studies that are in process or case studies that have been completed will be reviewed. The focus of the presentation will be on interventions that pharmacists can make while treating cGVHD and clinical pearls for currently approved options.
Learning Objectives:
Summarize the clinical features, pathophysiology, and grading for chronic graft versus host disease (cGVHD)
Describe front-line treatment for cGVHD and findings of the iNTEGRATE study
Review FDA approved agents for steroid refractory cGVHD - belumosudil(ROCKstar), ruxolitinib(REACH3), and ibrutinib
Discuss sequencing of agents, supportive care, and upcoming approvals for cGVHD agents
